Chinese Journal of Antituberculosis ›› 2018, Vol. 40 ›› Issue (9): 1007-1011.doi: 10.3969/j.issn.1000-6621.2018.09.020
• Short Articles • Previous Articles Next Articles
Received:
2018-05-13
Online:
2018-09-10
Published:
2018-10-17
Contact:
Tao JIN
E-mail:sysxkyysnk@163.com
Tao JIN. Dose adjustment of Immunosuppressants in anti-tuberculosis regimen containing rifampins (Report of three cases)[J]. Chinese Journal of Antituberculosis, 2018, 40(9): 1007-1011. doi: 10.3969/j.issn.1000-6621.2018.09.020
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2018.09.020
[1] | World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization, 2017. |
[2] |
裴宁, 卢水华 . WHO《潜伏性结核感染管理指南》要点解析及我国研究现状. 中国防痨杂志, 2015,37(7):736-739.
doi: 10.3969/j.issn.1000-6621.2015.07.005 URL |
[3] | 石炳毅, 王强, 王仲元 . 实体器官移植术后结核病的研究现状及进展. 器官移植, 2016,7(5):351-354. |
[4] | 田恒创, 高丽霞 . T-SPOT.TB对诊断系统性红斑狼疮合并活动性结核感染的意义. 石家庄:河北医科大学, 2015: 11-42. |
[5] | 王子洵, 荣兰香, 马淑红 , 等. 风湿免疫性疾病患者行T-SPOT.TB检测筛查潜伏性结核感染的价值. 中国实验诊断学, 2017,21(3):512-514. |
[6] | 张洁, 谭浩 . 利福平与其他药物相互作用研究进展. 天津药学, 2009,21(1):69-72. |
[7] |
张谞丰, 吕毅, 王博 , 等. 肝移植术后结核感染的诊断和治疗(并文献复习). 中国普通外科杂志, 2007,16(8):750-753.
doi: 10.3969/j.issn.1005-6947.2007.08.008 URL |
[8] |
张静, 周宏灏 . 异烟肼对CYP2C19和CYP3A4酶活性的影响及其与NAT2基因型的相关性. 长沙:中南大学, 2005.
doi: 10.7666/d.y747346 URL |
[9] | 文海棠 . 异烟肼联用常见药物的相互作用与合理性. 中国药业, 2015,24(8):79-80. |
[10] | 张实革 . 免疫抑制剂的进展与临床评价. 中国医院用药评价与分析, 2008,8(11):803-807. |
[11] | 李瑞东, 王正昕 . 免疫抑制剂在肝移植中的应用. 上海医药, 2016,37(1):7-10. |
[12] | 付平, 苟慎菊, 汤曦 . 免疫抑制剂在肾脏疾病中的合理应用-指南的个体化实践. 中华肾病研究电子杂志, 2014,3(4):173-176. |
[13] |
郭宁, 吴忠均 . 免疫抑制药物在肝移植中的应用现状. 中国组织工程研究, 2012,16(18):3375-3379.
doi: 10.3969/j.issn.1673-8225.2012.18.030 URL |
[14] |
金弢 . 临床行血液净化患者的抗结核药物使用规则. 结核病与肺部健康杂志, 2017,6(1):21-24.
doi: 10.3969/j.issn.2095-3755.2017.01.006 URL |
[15] | 林俊, 郭宏波, 唐雅望 , 等. 肾移植术后肺结核的临床特点及早期诊断的单中心经验. 临床和实验医学杂志, 2013,12(9):680-682. |
[16] | 王永斌, 李小平 . 利福平对糖皮质激素降解作用在结核性渗出性胸膜炎治疗中的对比研究. 中国当代医药, 2009,16(5):44-45. |
[17] | 左亚刚, 晋红中, 王宏伟 . 大疱性类天疱疮合并结核感染4例及文献复习. 协和医学杂志, 2012,3(4):375-380. |
[18] |
张铖, 钱叶勇 . 肾移植术后并发结核病的临床研究. 太原:山西医科大学, 2015: 1-27.
doi: 10.7666/d.D649930 URL |
[19] |
Chou NK, Wang JL, Chi NH , et al. Tuberculosis after heart transplantation: twenty years of experience in a single center in Taiwan. Transplant Proc, 2008,40(8):2631-2633.
doi: 10.1016/j.transproceed.2008.08.013 URL |
[20] |
毛文君, 夏维, 陈静瑜 . 肺移植术后并发肺结核1例. 中华胸心血管外科杂志, 2012,28(7):444.
doi: 10.3760/cma.j.issn.1001-4497.2012.07.022 |
[21] |
Subramanian AK, Morris MI , AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Trasplant, 2013,13 Suppl 4: 68-76.
doi: 10.1111/ajt.12100 URL pmid: 23465000 |
[22] |
黄正宇, 洪良庆, 毕小刚 , 等. 去利福平方案在肾移植术后结核菌感染中的临床应用. 中国器官移植杂志, 2008,29(8):492-494.
doi: 10.3760/cma.j.issn.0254-1785.2008.08.012 URL |
[23] |
张玲, 邓荣海, 刘龙山 , 等. 五酯片在肾移植术后含利福平抗结核治疗中的应用22例. 中国器官移植杂志, 2016,37(1):29-33.
doi: 10.3760/cma.j.issn.0254-1785.2016.01.007 URL |
[24] |
刘龙山, 王长希, 傅茜 , 等. 五酯片用于肾移植患者对他克莫司药代动力学的影响及长期疗效观察. 器官移植, 2012,3(1):33-36.
doi: 10.3969/j.issn.1674-7445.2012.01.008 URL |
[25] | Qin XL, Chen X, Wang Y , et al. In vivo to in vitro effects of six bioactive lignans of Wuzhi tablet(Schisandra sphenanthera extract)on the CYP3A/P-glycoprotein-mediated absorption and metabolism of tacrolimus. Drug Metab Dispos, 2014,42(1):193-199. |
[26] | 聂峰, 孙煦勇, 胡赟 , 等. 五酯片对口服他克莫司肾移植受者的影响. 中国中西医结合肾病杂志, 2011,12(3):223-225. |
[27] | 刘永光, 郭颖, 李留洋 , 等. 五酯胶囊对肾移植受者环孢素全血浓度的影响. 广东医学, 2010,31(5):641-642. |
[28] | 吴笑春, 李罄 . 肾移植患者应用环孢素的有效血药浓度范围. 中国医院药学杂志, 2000,20(3):173-175. |
[29] |
Lee KH, Shin JG, Chong WS , et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. Eur J Clin Pharmacol, 1993,45(3):287-289.
doi: 10.1007/BF00315399 URL |
[30] |
Kim YH, Yoon YR, Kim YW , et al. Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis. Transplant Proc, 1998,30(7):3570-3572.
doi: 10.1016/S0041-1345(98)01139-7 URL pmid: 9838563 |
[31] | 兰瑛 . 环孢素A 与抗结核药物合用患者的药学监护. 中国药师, 2015,18(2):268-270. |
[32] |
谭肖群, 徐嫦媛 . 肾移植术后并发结核病的护理. 现代医院, 2009,9(5):104-105.
doi: 10.3969/j.issn.1671-332X.2009.05.054 URL |
[33] |
王营, 曲明, 史彦芬 , 等. 肝移植后结核三例诊治体会. 中华器官移植杂志, 2013,34(3):184-185.
doi: 10.3760/cma.j.issn.0254-1785.2013.03.017 URL |
[34] | 赵冠人, 李国栋, 冯端浩 . 利福喷丁与利福平治疗肺结核的Meta分析. 中国药物应用与监测, 2012,9(2):73-77. |
[35] | 肖和平 . 耐药结核病化学治疗指南(2015年). 北京: 人民卫生出版社, 2015: 23-34. |
[36] |
Hickey MD, Quan DJ, Chin-Hong PV , et al. Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation. Liver Transpl, 2013,19(4):457-461.
doi: 10.1002/lt.v19.4 URL |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||